Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 24269888
Zhou Y, et al. (2014) p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett 588, 131-7 24269888
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T693-p - EGFR (human)
Modsite: RELVEPLtPsGEAPN SwissProt Entrez-Gene
Orthologous residues
EGFR (human): T693‑p, EGFR iso2 (human): , EGFR iso5 (human): T693‑p, EGFR (mouse): T695‑p, EGFR (rat): T694‑p, EGFR (pig): T693‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF increase

S1070-p - EGFR (human)
Modsite: DsFLQRyssDPtGAL SwissProt Entrez-Gene
Orthologous residues
EGFR (human): S1070‑p, EGFR iso2 (human): , EGFR iso5 (human): S1070‑p, EGFR (mouse): S1070‑p, EGFR (rat): S1069‑p, EGFR (pig): S1069‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF augment treatment-induced decrease

S1071-p - EGFR (human)
Modsite: sFLQRyssDPtGALt SwissProt Entrez-Gene
Orthologous residues
EGFR (human): S1071‑p, EGFR iso2 (human): , EGFR iso5 (human): S1071‑p, EGFR (mouse): S1071‑p, EGFR (rat): S1070‑p, EGFR (pig): S1070‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF augment treatment-induced decrease

Y1092-p - EGFR (human)
Modsite: tFLPVPEyINQsVPk SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1092‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S796-p - EPS15 (human)
Modsite: RsINkLDsPDPFkLN SwissProt Entrez-Gene
Orthologous residues
EPS15 (human): S796‑p, EPS15 (mouse): S798‑p, EPS15 (rat): S797‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) siRNA inhibition of enzyme, modification site within consensus motif, phospho-antibody, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF increase
IL-1b increase
osmotic_stress increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase
IL-1b increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase
IL-1b increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase
IL-1b increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase
IL-1b increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
TNF increase